Nintx raised $10 million in a Series A round led by Pitanga, Ecoa Capital, and MOV Investimentos to advance R&D for new drug programs utilizing Brazilian biodiversity.
PRIVATEDec 13, 2024
Amount Raised
$10 Million
Round Type
Series A
Sao PauloBiotechnologyHealth CarePharmaceutical
Investors
AdesteEcoa CapitalTiarajuMOV InvestimentosPitanga
Description
Nintx has successfully raised $10 million in a Series A funding round to support the research and development of new drug programs based on Brazil’s biodiversity. This funding will facilitate hiring researchers and introducing new technologies as part of their innovative biotech approach to treating multifactorial diseases.
Who to call at Nintx, and when
A new round usually means Nintx is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Nintx raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Nintx, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nintx. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Nintx
Location
Sao Paulo, Sao Paulo, Brazil
About
Nintx develops a new generation of medicines leveraging biodiversity, primarily from Brazil. One of its key innovations is a broader approach to tackling multifactorial diseases, caused by genetic and environmental factors as well as their interactions via the human gut microbiome. Multifactorial diseases include metabolic, immunological, cancer, and brain disorders. Nintx develops therapies targeting biological pathways directly and indirectly through gut microbiome modulation—both closely linked to the onset or worsening of multifactorial diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nintx raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.